Mark C. Leavitt

Cephalon, Inc. manufactures and distributes pharmaceutical products. It engages in the discovery and development of medicines for central nervous system disorders, pain, and cancer. The company was founded on August 24, 1987 by Frank Baldino, Jr. and is headquartered in Frazer, PA.

Medarex, Inc. provides commercial physical and biological research services. The company's UltiMAb, a human antibody development system creates and develops antibodies products for cancer, rheumatoid arthritis, inflammatory, autoimmune, and infectious diseases. The company was founded in 1987 and is headquartered in Princeton, New Jersey.

ViaCell, Inc. provides and develops cellular medicine for the treatment of diseases. The firm develops medicines for treatment of cancer, genetic disorders, organ transplant tolerance, neurological disorders, and autoimmune diseases. The company was founded in April 2000 and is headquartered in Cambridge, MA.

Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA.

Baker Bros. Advisors LP (BBA) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Julian Baker and Felix Baker in 2000 and do-business-as Baker Brothers Investments. BBA serves as a discretionary investment advisor to pooled investment vehicles operating as private investment funds and to a managed account.

InfaCare Pharmaceutical Corp. develops and commercializes proprietary pharmaceuticals for the neonatal and pediatric patient population. It offers Stanate, a heme oxygenase inhibitor for the treatment of infantile jaundice or hyperbilirubinemia. The company was founded by Robert A. Vukovich on July 5, 2005 and is headquartered in Trevose, PA.

Sarnoff Corp. provides contract research services in the fields of electronics, biomedicine and information technology. Its areas of research include optoelectronics, genomics, digital video, lasers and wireless communications. The company was founded in 1942 and is headquartered in Princeton, NJ.

Cobb-Vantress, Inc. operates a poultry research firm. It specializes in the development, production, and sale of broiler breeding stock. The company was founded in 1986 and is headquartered in Siloam Springs, AR.

Memory Pharmaceuticals Corp. develops pharmaceutical products for the treatment of debilitating central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. The company was founded by Axel Unterbeck in 1998 and is headquartered in Montvale, NJ.

Protez Pharmaceuticals, Inc. develops and manufactures pharmaceutical products. It develops antibiotics for infections & provides research service on intravenous & oral small molecule antibiotics to chronic and recurrent infections. The company was founded by Klaus Esser, Luigi Xerri & Christopher M. Cashman in 2003 and is headquartered in Malvern, PA.

Health Care Services, Inc. provides a range of healthcare services including home medical equipment, home infusion services, home care, and rehabilitation services. The private company is based in Augusta, GA.

The Children's Health Fund is a non-profit organization, which engages in the provision of healthcare services for kids. It offers Blue Bus, a pediatric mobile medical clinic that offers curbside checkups and treatments. The firm also supports the Terra Firma project, a program the provides healthcare, mental health support, and legal assistance for unaccompanied immigrant minors. The company was founded by Irwin E. Redlener, Karen B. Redlener, and Paul Simon in 1987 and is headquartered in New York, NY.

Javelin Pharmaceuticals, Inc. develops pharmaceutical drugs. It is a specialty pharmaceutical company that applies innovative proprietary technologies to develop new drugs and improved formulations of existing drugs that target current unmet and underserved medical market. The company's product candidates address the acute moderate-to-severe pain medication market segment. It has three late stage product candidates in development: Dyloject (diclofenac sodium, injectable), Rylomine (intranasal morphine) and PMI-150 (intranasal ketamine). The company was founded on February 23, 1998 and is headquartered in Cambridge, MA.

The American College of Clinical Pharmacology (ACCP) is an organization that focuses on clinical pharmacology. The American company's personal data privacy policy and procedure outlines how they collect, use, share, and protect personal data from their users.

Part of AstraZeneca PLC, AstraZeneca, Inc. manufactures vaccines.

Y-Prime LLC provides eClinical software and professional services. It offers patient and IP management, site monitoring, clinical outcomes, supply forecasting and professional services. The company was founded by Shawn Blackburn and Jaime Cook in 2006 and is headquartered in Malvern, PA.

Vivelix Pharmaceuticals, Ltd. manufactures and sells pharmaceutical products. The private company is based in Hamilton, BM. and has subsidiaries in the United States. The Bermudian company was founded by William P. Forbes.

Lord Abbett Credit Opportunities Fund is a closed-end management investment company that continuously offers its common shares and is operated as an interval fund. The company was founded on September 18, 2018 and is Headquartered in Jersey City, NJ.

Notch Therapeutics, Inc. engages in the development of cell therapies for the treatment of diseases. It offers technology platform, which uses genetically tailored stem cells as a renewable source for creating allogeneic T cell therapies that expand treatment options and deliver cell immunotherapies to patients. The company was founded by Juan Carlos Zuniga-Pflucker and Peter Zandstra in 2018 and is headquartered in Toronto, Canada.

Papyrus Therapeutics, Inc. is a preclinical stage biopharma American company that focuses on developing cancer therapeutics based on a novel target, opioid-binding cell adhesion molecule (OPCML). Papyrus Therapeutics is based in Oxford, UK. The company's expertise in this target is based on years of research and multiple publications by the company's co-founder and chief scientific adviser, Professor Hani Gabra. The company was founded by Paul Blake and Hani Gabra, and Paul Blake has been the CEO since incorporation.